These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 34988095)

  • 1. Sodium-Glucose Cotransporter 2 Inhibitors Mechanisms of Action: A Review.
    Fonseca-Correa JI; Correa-Rotter R
    Front Med (Lausanne); 2021; 8():777861. PubMed ID: 34988095
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of Sodium-Glucose Cotransporter Inhibitor Use in Type 2 Diabetes Mellitus Patients With Heart Failure.
    Choday S; Ravi N; Parisapogu A; Ojinna BT; Sherpa ML
    Cureus; 2023 Feb; 15(2):e34687. PubMed ID: 36909046
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multi-Organ Protective Effects of Sodium Glucose Cotransporter 2 Inhibitors.
    Yanai H; Hakoshima M; Adachi H; Katsuyama H
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33922546
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardioprotection conferred by sodium-glucose cotransporter 2 inhibitors: a renal proximal tubule perspective.
    Silva Dos Santos D; Polidoro JZ; Borges-Júnior FA; Girardi ACC
    Am J Physiol Cell Physiol; 2020 Feb; 318(2):C328-C336. PubMed ID: 31721613
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sodium-glucose cotransporter inhibitors and kidney fibrosis: review of the current evidence and related mechanisms.
    Afsar B; Afsar RE
    Pharmacol Rep; 2023 Feb; 75(1):44-68. PubMed ID: 36534320
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sodium-Glucose Cotransporter-2 Inhibition and the Glomerulus: A Review.
    Kalra S; Singh V; Nagrale D
    Adv Ther; 2016 Sep; 33(9):1502-18. PubMed ID: 27423646
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition.
    Vallon V; Thomson SC
    Diabetologia; 2017 Feb; 60(2):215-225. PubMed ID: 27878313
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of renal and cardiovascular protection mechanisms of SGLT2 inhibitors: model-based analysis of clinical data.
    Hallow KM; Greasley PJ; Helmlinger G; Chu L; Heerspink HJ; Boulton DW
    Am J Physiol Renal Physiol; 2018 Nov; 315(5):F1295-F1306. PubMed ID: 30019930
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sodium-glucose Cotransporter 2 Inhibitors (SGLT2i): Their Role in Cardiometabolic Risk Management.
    Katsiki N; Mikhailidis DP; Theodorakis MJ
    Curr Pharm Des; 2017; 23(10):1522-1532. PubMed ID: 28088910
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SGLT2 inhibitors, sodium and off-target effects: an overview.
    De Pascalis A; Cianciolo G; Capelli I; Brunori G; La Manna G
    J Nephrol; 2021 Jun; 34(3):673-680. PubMed ID: 32870494
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SGLT2 is not expressed in pancreatic α- and β-cells, and its inhibition does not directly affect glucagon and insulin secretion in rodents and humans.
    Chae H; Augustin R; Gatineau E; Mayoux E; Bensellam M; Antoine N; Khattab F; Lai BK; Brusa D; Stierstorfer B; Klein H; Singh B; Ruiz L; Pieper M; Mark M; Herrera PL; Gribble FM; Reimann F; Wojtusciszyn A; Broca C; Rita N; Piemonti L; Gilon P
    Mol Metab; 2020 Dec; 42():101071. PubMed ID: 32896668
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sodium-glucose cotransporter 2 inhibitors (SGLT2i): renal implications.
    Castañeda AM; Dutra-Rufato A; Juarez MJ; Grosembacher L; Gonzalez-Torres H; Musso CG
    Int Urol Nephrol; 2021 Feb; 53(2):291-299. PubMed ID: 32767250
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiorenal Protections of SGLT2 Inhibitors in the Treatment of Type 2 Diabetes.
    Nazari S; Mirkhani H
    Curr Diabetes Rev; 2023; 19(8):e221222212126. PubMed ID: 36567296
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Rationale and Evidence for SGLT2 Inhibitors as a Treatment for Nondiabetic Glomerular Disease.
    Miyata KN; Zhang SL; Chan JSD
    Glomerular Dis; 2021 Apr; 1(1):21-33. PubMed ID: 36751486
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanisms of Protective Effects of SGLT2 Inhibitors in Cardiovascular Disease and Renal Dysfunction.
    Liu B; Wang Y; Zhang Y; Yan B
    Curr Top Med Chem; 2019; 19(20):1818-1849. PubMed ID: 31456521
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SGLT2 Inhibitors and the Diabetic Kidney.
    Fioretto P; Zambon A; Rossato M; Busetto L; Vettor R
    Diabetes Care; 2016 Aug; 39 Suppl 2():S165-71. PubMed ID: 27440829
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors: Benefits Versus Risk.
    Jasleen B; Vishal GK; Sameera M; Fahad M; Brendan O; Deion S; Pemminati S
    Cureus; 2023 Jan; 15(1):e33939. PubMed ID: 36819350
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Model-Based Evaluation of Proximal Sodium Reabsorption Through SGLT2 in Health and Diabetes and the Effect of Inhibition With Canagliflozin.
    Brady JA; Hallow KM
    J Clin Pharmacol; 2018 Mar; 58(3):377-385. PubMed ID: 29144539
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of sodium glucose cotransporter 2 (SGLT2) inhibitors on atherosclerosis: from pharmacology to pre-clinical and clinical therapeutics.
    Liu Z; Ma X; Ilyas I; Zheng X; Luo S; Little PJ; Kamato D; Sahebkar A; Wu W; Weng J; Xu S
    Theranostics; 2021; 11(9):4502-4515. PubMed ID: 33754074
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of sodium glucose co-transporter 2 inhibitors on the kidney.
    de Albuquerque Rocha N; Neeland IJ; McCullough PA; Toto RD; McGuire DK
    Diab Vasc Dis Res; 2018 Sep; 15(5):375-386. PubMed ID: 29963920
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.